Aldosterone and Dexamethasone Activate African Lungfish Mineralocorticoid Receptor:
Increased Activation After Removal of the Amino-Terminal Domain

Yoshinao Katsu^{1,2}, Shin Oana², Xiaozhi Lin², Susumu Hyodo³, Michael E. Baker⁴

¹Graduate School of Life Science

Hokkaido University

Sapporo, Japan

²Faculty of Sciences

Hokkaido University

Sapporo, Japan

³Laboratory of Physiology

Atmosphere and Ocean Research Institute

University of Tokyo

Chiba, Japan

⁴Division of Nephrology-Hypertension

Department of Medicine, 0693

University of California, San Diego

9500 Gilman Drive

La Jolla, CA 92093-0693

Center for Academic Research and Training in Anthropogeny (CARTA)

University of California, San Diego

La Jolla, CA 92093

Correspondence to:

Y. Katsu: ykatsu@sci.hokudai.ac.jp

M. E. Baker: mbaker@ucsd.edu

ABSTRACT. Aldosterone, the main physiological mineralocorticoid in humans and other terrestrial vertebrates, first appears in lungfish, which are lobe-finned fish that are forerunners of terrestrial vertebrates. Aldosterone activation of the MR regulates internal homeostasis of water, sodium and potassium, which was critical in the conquest of land by vertebrates. We studied transcriptional activation of the slender African lungfish MR by aldosterone, other corticosteroids and progesterone and find that aldosterone, 11-deoxycorticosterone, 11-deoxycortisol and progesterone have half-maximal responses (EC₅₀s) below 1 nM and are potential physiological mineralocorticoids. In contrast, EC₅₀s for corticosterone and cortisol were 23 nM and 66 nM, respectively. Unexpectedly, truncated lungfish MR, consisting of the DNA-binding, hinge and steroid-binding domains, had a stronger response to corticosteroids and progesterone than full-length lungfish MR, indicating that the N-terminal domain represses steroid activation of lungfish MR, unlike human MR in which the N-terminal domain contains an activation function. BLAST searches of GenBank did not retrieve a GR ortholog, leading us to test dexamethasone and triamcinolone for activation of lungfish MR. At 10 nM, both synthetic glucocorticoids are about 4-fold stronger than 10 nM aldosterone in activating full-length lungfish MR, leading us to propose that lungfish MR also functions as a GR.

Keywords: Lungfish, Lobe-finned Fish, Terrestrial Vertebrates, Aldosterone evolution; mineralocorticoid receptor evolution; evolution

INTRODUCTION

The mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) belong to the nuclear receptor family, a diverse group of transcription factors that arose in multicellular animals [1–3]. The MR and GR have key roles in the physiology of humans and other terrestrial vertebrates and fish [4–11]. The MR and GR evolved from an ancestral corticoid receptor (CR) in a jawless fish (cyclostome), which has descendants in modern lampreys and hagfish [12–14]. A distinct MR and GR first appear in cartilaginous fishes (Chondrichthyes) [1,13,15–17], which diverged from bony vertebrates about 450 million years ago [18,19].

Aldosterone is the main physiological mineralocorticoid in humans and other terrestrial vertebrates [5,6,9,20–23]. Aldosterone activation of the MR in the kidney regulates salt and

water homeostasis by promoting sodium and water reabsorption and potassium secretion, a mechanism that conserves salt and water. Thus, it is puzzling that aldosterone is a potent transcriptional activator of lamprey and hagfish CRs [15], skate MR [16] and elephant shark MR [13,24] because aldosterone is not synthesized by lampreys [15], cartilaginous fishes or ray finned fishes [25]. Aldosterone first appears in lungfish [26–28], which are lobe-finned fish that are forerunners of terrestrial vertebrates [29–31]. The key phylogenetic position of lungfish in the transition of vertebrates from water to land [27,29,30,32] and the role of the MR in maintaining internal electrolyte homeostasis [5,8,33,34] motivated us to investigate the response of the slender African lungfish MR to aldosterone, cortisol and other corticosteroids (Figure 1), as well as activation by progestins, which also activate elephant shark MR [24], ray-finned fish MR [35–39] and chicken MR [24,40].

Figure 1. Structures of Corticosteroids, Dexamethasone, Triamcinolone, Progesterone and Spironolactone. Aldosterone and 11-deoxycorticosterone are mineralocorticoids [41]. 11-deoxycortisol is a mineralocorticoid in lamprey [42,43]. Cortisol and corticosterone are glucocorticoids in terrestrial vertebrates and ray-finned fish [41,44]. Dexamethasone and

triamcinolone are synthetic glucocorticoids. Progesterone is female reproductive steroid that also is important in male physiology [45,46]. Spironolactone is a mineralocorticoid antagonist in humans [47,48].

Our investigation also uncovered an unexpected role of the N-terminal domain (NTD) of lungfish MR in inhibiting transcriptional activation by steroids. Like other steroid receptors, lungfish MR is a multi-domain protein, consisting of an NTD (domains A and B), a central DNA-binding domain (DBD) (domain C), a hinge domain (D) and a C-terminal ligand-binding domain (LBD) (domain E) [49–51] (Figure 2). The NTD in the human MR contains an activation function domain (AF1), which is split into two segments [49–51]. (Figure 2). As described below, we find that in contrast to human MR [24,49,51,52], the NTD in full-length lungfish MR reduces steroid-mediated activation of lungfish MR, compared to truncated lungfish MR-CDE in cells transfected with a 3X-Tyrosine Amino Transferase (TAT3) promoter [53].

We also find that lungfish MR is activated by dexamethasone. At 10 nM, dexamethasone activates full-length lungfish MR and truncated lungfish MR with a signal that is 4-fold and 6-fold stronger, respectively, than that of 10 nM aldosterone. This strong response to dexamethasone and the absence of a lungfish GR sequence after a BLAST search of GenBank leads us to propose that lungfish MR also functions as a GR.

Figure 2. Comparison of the functional domains of lungfish MR to corresponding domains in selected vertebrate MRs (human, coelacanth, elephant shark, *Xenopus*, zebrafish) and GRs (human, coelacanth, elephant shark). Lungfish MR and human MR have 97% and 74% identity in DBD and LBD, respectively. Lungfish MR and elephant shark MR have 92% and 68% identity in DBD and LBD, respectively. This strong conservation of the DBD and LBD contrasts with the low sequence identity of 44% and 47% between their NTDs. There are similar % identities between corresponding domains in lungfish MR and other MRs.

RESULTS

Transcriptional activation of full-length and truncated lungfish MR by corticosteroids, progestins and dexamethasone.

We screened a panel of steroids (Figure 1) at 10 nM for transcriptional activation of full-length and truncated lungfish MR containing the CDE domains (MR-CDE) using two promoters: 2X-Mouse Mammary Tumor Virus (MMTV) [54,55] and TAT3 [53], which along with plasmids for both lungfish MRs were transfected into HEK293 cells.

As shown in Figure 3A, there was about 2 to 3-fold activation by 10 nM aldosterone, other corticosteroids or progesterone of full-length lungfish MR using the MMTV-luc reporter and less steroid activation of lungfish MR-CDE (Figure 3B).

Interestingly, compared to activation of full-length lungfish MR with the MMTV promoter (Figure 3A), transcriptional activation of full-length lungfish MR with a TAT3 promoter and 10 nM aldosterone, other physiological corticosteroids or dexamethasone increased by about 1.5 to 2-fold (Figure 3C). Unexpectedly, lungfish MR-CDE with the TAT3 promoter had an additional 2-fold increase in activation by all corticosteroids (Figure 3D). Progesterone activated lungfish MR in accord with the prediction of Fuller et al. [37,39,56]. Together, these experiments show that removal of the NTD increases corticosteroid and progesterone activation of lungfish MR in the presence of the TAT3 promoter.

Our results with dexamethasone, which activates human MR [52,57–59], were unexpected. To our surprise, compared to aldosterone, dexamethasone was about 3-fold and 6-fold more active, respectively, in activating full-length lungfish MR (Figure 3C) and truncated lungfish MR (Figure 3D) with the TAT3 promoter. Moreover, both cortisol and corticosterone have stronger fold-activation than does aldosterone of lungfish MR using the TAT3 promoter. Under these conditions, lungfish MR appears to have a GR-like response to steroids.

Figure 3. Ligand specificity of full-length and truncated lungfish MR.

Plasmids for full-length lungfish MR or truncated lungfish MR (MR-CDE) were expressed in HEK293 cells with an MMTV-luciferase reporter or a TAT3-luciferase reporter. Transfected cells were treated with either 10 nM aldosterone, cortisol, 11-deoxycortisol, corticosterone, 11-deoxycorticosterone, progesterone, dexamethasone or vehicle alone (DMSO). Results are expressed as means $\pm$ SEM, n=3. Y-axis indicates fold-activation compared to the activity of control vector with vehicle alone as 1. A. Full-length lungfish MR with MMTV-luciferase. B. Truncated lungfish MR (MR-CDE) with MMTV-luciferase. C. Full-length lungfish MR with TAT3-luciferase. D. Truncated lungfish MR (MR-CDE) with TAT3-luciferase.

Spironolactone and eplerenone are transcriptional activators of lungfish MR.

Because spironolactone, an antagonist of human MR, activates elephant shark MR [24], zebrafish MR [37,40,60] and trout MR [38], we investigated spironolactone for activation of full-length lungfish MR and truncated lungfish MR-CDE. We also studied activation by eplerenone, another antagonist of human MR [61]. As shown in Figure 4, both spironolactone and eplerenone activated lungfish MR with a TAT3 promoter, and there was a further increase in fold-activation by both steroids of lungfish MR-CDE.

Figure 4. Spironolactone and eplerenone activation of full-length and truncated lungfish MR. Plasmids for full-length lungfish MR or truncated lungfish MR (MR-CDE) were expressed in HEK293 cells with a TAT3-luciferase reporter. Transfected cells were treated with either 10 nM or 100 nM aldosterone, spironolactone or eplerenone or vehicle alone (DMSO). Results are expressed as means $\pm$ SEM, n=3. Y-axis indicates fold-activation compared to the activity of control vector with vehicle alone as 1. A. Full-length lungfish MR with TAT3. B. Truncated lungfish MR (MR-CDE) with TAT3.

Concentration-dependent activation by corticosteroids and progestins of full-length and truncated lungfish MR.

To gain a quantitative measure of corticosteroid and progestin activation of full-length and truncated lungfish MR, we determined the concentration dependence of transcriptional activation by corticosteroids and progestins of full-length lungfish MR and lungfish MR-CDE using TAT3 (Figure 5). This data was used to calculate a half maximal response (EC50) for steroid activation of lungfish MR with a TAT3 promoter (Table 1). For full-length lungfish MR, the four lowest EC50s were for aldosterone (0.04nM), 11-deoxycorticosterone (0.04 nM), 11-deoxycortisol (0.17nM) and progesterone (0.03nM). These low EC50s are consistent with a physiological role for one or more of these steroids as ligand for lungfish MR. In contrast, corticosterone and cortisol, two physiological corticosteroids in terrestrial vertebrates, had EC50s of 23.1nM and 66.1nM, respectively. Two synthetic glucocorticoids, dexamethasone and triamcinolone, had EC50s of 4.7nM and 1.3nM, respectively.

For truncated lungfish MR, there were similar low EC50s for aldosterone (0.24nM), 11-deoxycorticosterone (0.013nM), 11-deoxycortisol (0.27nM) and progesterone (0.04nM). EC50s for corticosterone and cortisol were 85.5nM and 86.7nM, respectively. EC50s for dexamethasone and triamcinolone were 7.7nM and 2.4nM, respectively.

Overall, these results reveal that the EC50s of aldosterone, 11-deoxycorticosterone, 11-deoxycortisol and progesterone for full-length lungfish MR and lungfish MR-CDE are similar and that one or more of these steroids could be a physiological mineralocorticoid in lungfish. Although EC50s for full-length lungfish MR of triamcinolone and dexamethasone were at least 10-fold higher than that of aldosterone, deoxycorticosterone, 11-deoxycortisol and progesterone, compared to these steroids, dexamethasone and triamcinolone have a several fold higher activation of full-length and truncated lungfish MR (Figure 5). Consistent with data in Figure 3, deletion of the NTD to form truncated lungfish MR-CDE increased fold-activation by aldosterone, the other corticosteroids, progesterone, dexamethasone and triamcinolone. However, deletion of the NTD did not have a large effect on their EC50s.

Fig. 5. Concentration-dependent transcriptional activation by corticosteroids, progesterone, dexamethasone and triamcinolone of full length and truncated lungfish MR. Plasmids for full-length lungfish MR or truncated lungfish MR, were expressed in HEK293 cells with a TAT3-luciferase promoter. Cells were treated with increasing concentrations of either aldosterone, cortisol, corticosterone, 11-deoxycorticosterone, 11-deoxycortisol, progesterone, dexamethasone and triamcinolone or vehicle alone (DMSO). Results are expressed as means $\pm$ SEM, n=3. Y-axis indicates fold-activation compared to the activity of control vector with vehicle (DMSO) alone as 1. A. Aldosterone, 11-deoxycorticosterone, 11-deoxycortisol and progesterone with full-length lungfish MR with TAT3-luc. B. Aldosterone, 11-deoxycorticosterone, 11-deoxycortisol and progesterone with truncated lungfish MR (Domains CDE) with TAT3-luc. C. Cortisol, corticosterone, dexamethasone and triamcinolone with full-length lungfish MR with TAT3-luc. D. Cortisol, corticosterone, dexamethasone and triamcinolone with truncated lungfish MR (Domains CDE) with TAT3-luc.

Table 1. EC50 values for steroid activation of full-length and truncated lungfish MR with the TAT3 promoter.

	Aldosterone	11-deoxycorticosterone	11-deoxycortisol	Progesterone
	EC50	EC50	EC50	EC50
MR-full length	0.04 nM	0.04 nM	0.17 nM	0.03 nM
95% confidence interval	0.02-0.07 nM	0.02-0.09 nM	0.1-0.3 nM	0.02-0.06 nM
MR-CDE	0.24 nM	0.13 nM	0.27 nM	0.044 nM
95% confidence interval	0.17-0.35 nM	0.08-0.2 nM	0.14-0.53 nM	0.026-0.076 nM

	Corticosterone	Cortisol	Triamcinolone	Dexamethasone
	EC50	EC50	EC50	EC50
MR-full length	23.1 nM	66.1 nM	1.3 nM	4.7 nM
95% confidence interval	11.3-47.1 nM	44.5-98.4 nM	0.9-1.9 nM	3.3-6.9 nM
MR-CDE	85.5 nM	86.7 nM	2.4 nM	7.7 nM
95% confidence interval	60.0-121.8 nM	74.3-101.2 nM	2.1-2.8 nM	6.6-9.1 nM

Transcriptional activation of full-length and truncated human MR and full-length and truncated elephant shark MR by corticosteroids and progestins.

To gain an evolutionary perspective on activation of lungfish MR by steroids, we screened a panel of steroids, at 10 nM, for transcriptional activation of full-length human and elephant shark MRs and truncated human and elephant shark MR-CDEs using two reporters: MMTV-luc and TAT3-luc.

Comparison of human MR and lungfish MR.

Overall, compared to lungfish MR, fold activation of human MR was significantly higher for aldosterone and other corticosteroids. For example, compared to 2-fold activation by aldosterone of full-length lungfish MR with the MMTV promoter (Figure 3A), activation of full-length human MR by aldosterone was about 70-fold with the MMTV promoter (Figure 6A). Although fold-activation by steroids for truncated human MR (Figure 6B) decreased compared to full-length human MR (Figure 6A), activation by aldosterone and other corticosteroids of truncated human MR with the MMTV promoter (Figure 6B) was about 7-fold higher than for truncated lungfish MR (Figure 3B).

Unlike for lungfish MR, deletion of the NTD in human MR resulted in a loss of activation by aldosterone and other corticosteroids for human MR-CDE with both promoters (Figure 6A-D), consistent with the presence of two activation function domains in the NTD (Figure 2) [49–52]. The relative loss of activation of human MR was greater with the MMTV promoter than with the TAT3 promoter. For example, at 10 nM aldosterone, activation of full-length human MR with the MMTV reporter was 70-fold (Figure 6A), which decreased to 14-fold for human MR-CDE (Figure 6B). In contrast, at 10 nM aldosterone, fold-activation of human MR-CDE with the TAT3 promoter was about 75% of activity for full-length human MR (Figure 6C, D). However, 11-deoxycorticosterone and 11-deoxycortisol lost substantial activity for human MR-CDE with the MMTV and TAT3 promoters (Figure 6D).

There also was higher fold-activation by aldosterone of full-length and truncated human MR with the TAT3 promoter (Figure 6C, D) compared to full-length and truncated lungfish MR (Figure 3C, D). Aldosterone activation of full-length human MR with the TAT3 promoter (Figure 6C) was about 45-fold higher than that for full-length lungfish MR with the TAT3 promoter (Figure 3C). Aldosterone activation of human MR-CDE with the TAT3 promoter (Figure 6D) was about 15-fold higher than that for lungfish MR-CDE (Figure 3D).

The relative activation by aldosterone and dexamethasone of human MR and lungfish MR was reversed. Aldosterone was more active than dexamethasone in stimulating transcription by full-length human MR and human MR-CDE with the TAT3 promoter (Figure 6C, D). In contrast, for lungfish MR dexamethasone was more active than aldosterone for full-length lungfish MR and lungfish MR-CDE with the TAT3 promoter (Figure 3C, D).

Comparison of elephant shark MR and lungfish MR.

Activation by corticosteroids and progesterone of elephant shark MR with the MMTV promoter has some similarities with their activation of lungfish MR. Like lungfish MR, corticosteroids have a similar activation of about 10-fold for full-length and truncated elephant shark MR, with little difference in potency among the corticosteroids. However, unlike lungfish MR, aldosterone is stronger than dexamethasone in activating full-length and truncated elephant shark MR with the MMTV promoter (Figure 6E, F).

At a 10 nM steroid concentration, aldosterone and other corticosteroids activated full-length elephant shark MR with the TAT3 promoter by 9 to 12-fold (Figure 6G), which was similar to activation with the MMTV promoter (Figure 6E). Activation of full-length elephant shark MR by progesterone was about 5-fold with the TAT3 and MMTV promoters (Figure 6E, G). Aldosterone was about 2-fold more active than dexamethasone.

However, deletion of the NTD from elephant shark MR resulted in a significant increase in activation by steroids in the presence of the TAT3 promoter (Figure 6H). Thus, truncated elephant shark MR with the TAT3 promoter was activated from 300 to 350-fold by aldosterone and other corticosteroids and about 200-fold by progesterone and dexamethasone (Figure 6H), indicating that like lungfish MR, the NTD in elephant shark inhibits activation by corticosteroids. However, unlike lungfish MR, compared to aldosterone, dexamethasone was less active for full-length and truncated elephant shark MR with the MMTV promoter and truncated elephant shark MR with the TAT3 promoter.

Figure 6. Ligand specificity of full-length and truncated human MR and elephant shark

MR. Plasmids for full-length human and elephant shark MR or truncated human and elephant shark MR (MR-CDE) were expressed in HEK293 cells with an MMTV-luciferase reporter or a TAT3-luciferase reporter. Transfected cells were treated with either 10 nM aldosterone, cortisol, 11-deoxycortisol, corticosterone, 11-deoxycorticosterone, progesterone, dexamethasone or vehicle alone (DMSO). Results are expressed as means $\pm$ SEM, n=3. Y-axis indicates fold-activation compared to the activity of control vector with vehicle alone as 1. A. Full-length human MR with MMTV-luciferase. B. Truncated human MR (MR-CDE) with MMTV-luciferase. C. Full-length elephant shark MR with TAT3-luciferase. D. Truncated elephant shark MR (MR-CDE) with TAT3-luciferase.

Does lungfish contain a separate GR gene?

We used sequences of human GR, coelacanth GR and elephant shark GR as probes in a BLAST search of GenBank and did not retrieve a lungfish GR sequence. The absence of a lungfish GR ortholog coupled with the strong response of lungfish MR to dexamethasone and triamcinolone (Figure 5) leads us to propose that lungfish MR also functions as a GR.

Discussion

Dobzhansky's aphorism "Nothing in Biology Makes Sense Except in the Light of Evolution" [62] explains the importance of the evolution of aldosterone in lungfish because aldosterone activation of the kidney MR in terrestrial vertebrates regulates sodium, potassium and water transport, which is critical in maintaining internal electrolyte homeostasis in terrestrial vertebrates [30,34,63–65] an activity that was important in the transition from water to land. Here we report that aldosterone, 11-deoxycorticosterone, and progesterone have EC50s below 1 nM for lungfish MR (Table 1), which makes these steroids potential physiological ligands for lungfish MR. Another potential physiological steroid is 11-deoxycortisol, which is a steroid for

the CR in Atlantic sea lamprey [42,43]. 11-deoxycortisol has EC₅₀ of 0.17 nM for full-length lungfish MR (Table 1).

A functional advantage of 11-deoxycorticosterone, 11-deoxycortisol and progesterone as ligands for the MR is that they lack an 11 β -hydroxyl group, and thus, like aldosterone, they are inert to 11 β -hydroxysteroid dehydrogenase-type 2, unlike cortisol and corticosterone [66–69]. Indeed, this inertness to 11 β -hydroxysteroid dehydrogenase-type 2 and the low EC₅₀s of these steroids for lungfish MR suggests that more than one corticosteroid and progesterone [39] may be physiological mineralocorticoids.

Like ray-finned fish MRs [24,37,38,60] and elephant shark MR [24,39], lungfish MR is activated by spironolactone (Figure 4), and, as reported here, by eplerenone [47,48,61].

We also find important differences between the response of lungfish MR and human MR to aldosterone, 11-deoxycorticosterone, 11-deoxycortisol and progesterone, indicating that further selectivity for aldosterone in human MR occurred during the evolution of terrestrial vertebrates [13,15,37,40,52,69,70].

An unexpected difference between lungfish MR and human MR is the substantial increase in fold-activation by steroids of lungfish MR after deletion of the NTD, in contrast to human MR in which the NTD contains an activation function domain (Figure 2) [49–52]. Deletion of the NTD in elephant shark MR also resulted in a substantial increase in fold-activation by corticosteroids and progesterone using the TAT3 promoter (Figure 6), but not for the MMTV promoter [17]. These data with lungfish MR and elephant shark MR suggest that early in the evolution of the MR there was an allosteric interaction between the LBD and NTD [71,72] that repressed steroid activation of the MR, and that the activation function in the NTD as found in human MR [49–52] evolved later in terrestrial vertebrates, along with changes in

steroid specificity, such loss of MR activation by progesterone [37,39,70]. The different responses of full-length and truncated lungfish MR, human MR and elephant shark MR with the MMTV and TAT3 promoters indicate that the NTD and the promoter are important regulators of steroid activation of these MRs. Corticosteroid activation of these MRs in the presence of other promoters merits investigation.

The stronger response of lungfish MR to dexamethasone compared to aldosterone and the absence a lungfish GR ortholog sequence are puzzling. At a 10 nM concentration, fold-activation by dexamethasone and triamcinolone is substantially higher than that of cortisol, corticosterone, as well as aldosterone, 11-deoxycorticosterone, 11-deoxycortisol and progesterone for lungfish MR (Figure 5). One explanation is that lungfish MR also has a GR function.

Materials and Methods

Chemical reagents

Aldosterone, cortisol, corticosterone, 11-deoxycorticosterone, 11-deoxycortisol and progesterone, spironolactone and eplerenone were purchased from Sigma-Aldrich. For reporter gene assays, all hormones were dissolved in dimethyl-sulfoxide (DMSO); the final DMSO concentration in the culture medium did not exceed 0.1%.

Animal

A slender spotted African lungfish, *Protopterus dolloi*, was purchased from a local commercial supplier. Lungfish were anesthetized in freshwater containing 0.02% ethyl 3-aminobenzoate methane-sulfonate from Sigma-Aldrich, and tissue samples were quickly

dissected and frozen in liquid nitrogen. Animal handling procedures conformed to the guidelines set forth by the Institutional Animal Care and Use Committee at the University of Tokyo.

Molecular cloning of lungfish mineralocorticoid receptor

Two conserved amino acid regions, GCHYGV and LYFAPD of vertebrate MRs were selected and degenerate oligonucleotides were used as primers for PCR. First-strand cDNA was synthesized from 2 µg of total RNA isolated from the liver after amplification, and an additional primer set (CKVFFK and LYFAPD) was used for the second PCR. The amplified DNA fragments were subcloned with TA-cloning plasmid pGEM-T Easy vector, sequenced using a BigDye terminator Cycle Sequencing-kit with T7 and SP6 primers, and analyzed on the 3130 Genetic Analyzer (Applied Biosystems). The 5'- and 3'-ends of the mineralocorticoid receptor cDNAs were amplified by rapid amplification of the cDNA end (RACE) using a SMART RACE cDNA Amplification kit. Genbank accessions for this lungfish MR are: Nucleotide ID: LC630795 and Protein ID: BCV19931.

Construction of plasmid vectors

The full-length and truncated MRs were amplified by PCR with KOD DNA polymerase. The PCR products were gel-purified and ligated into pcDNA3.1 vector (Invitrogen). The truncated MR proteins were designed to possess methionine and valine residues at the N-terminus and contain a DNA-binding domain, a hinge-region, and a ligand-binding domain. The truncated MRs were amplified by PCR with KOD DNA polymerase by using the following primers: lungfish MR forward primer (5'-CAAGCTTACCATGGTGTGTCTGGTGTGTGGTGACGAAG-3' containing *Hind*III site) and lungfish MR reverse primer (5'-CCTACTTCCTGTGAAAGTACAATGAC -3' containing stop

codon), human MR forward primer (5'-
CGGATCCACCATGGTGTGTTTGGTGTGTGGGGATGAG-3' containing *Bam*HI site) and
human MR reverse primer (5'-CTCACTTCCGGTGGGAAGTAGAGCGGC -3' containing stop
codon). The amplified DNA fragments were subcloned with TA-cloning plasmid pGEM-T Easy
vector and sequenced, and then subcloned into pcDNA 3.1 vector by using *Hind*III-*Not*I sites for
lungfish MR truncated form or *Bam*HI-*Not*I sites for human MR truncated form. Mouse
mammary tumor virus-long terminal repeat (MMTV-LTR) was amplified from pMSG vector by
PCR, and inserted into pGL3-basic vector containing the *Photinus pyralis* luciferase gene. 3X-
Tyrosine Amino Transferase (TAT3) promoter containing reporter vector named pGL4.23-
TAT3-Luc was constructed as described previously [53]. All cloned DNA sequences were
verified by sequencing.

Transactivation assay and statistical methods

Transfection and reporter assays were carried out in HEK293 cells, as described previously
[40,73]. All experiments were performed in triplicate. The values shown are mean $\pm$ SEM from
three separate experiments, and dose-response data, which were used to calculate the half
maximal response (EC50) for each steroid, were analyzed using GraphPad Prism.

DECLARATION OF INTEREST

We have no conflict of interest.

ACKNOWLEDGEMENT

We thank Peter Fuller, Ron de Kloet, Patrick Prunet and Bernard Rossier for constructive
comments about an earlier version of this manuscript.

396

397 **AUTHOR CONTRIBUTIONS**

398 Y.K., S.O., and M.E.B. carried out the research and analyzed data. S.H. aided in the collection
399 of animals. X.L. constructed plasmid DNAs used in this study. Y.K. and M.E.B. conceived and
400 designed the experiments. Y.K. and M.E.B. wrote the paper. All authors gave final approval for
401 publication.

402

403 **FUNDING**

404 Y.K. was supported in part by Grants-in-Aid for Scientific Research [19K067309] from the
405 Ministry of Education, Culture, Sports, Science and Technology of Japan, and Takeda Science
406 Foundation. M.E.B. was supported by Research fund #3096.

407

408 **REFERENCES**

- 409 1. Baker ME, Nelson DR, Studer RA. Origin of the response to adrenal and sex steroids:
410 Roles of promiscuity and co-evolution of enzymes and steroid receptors. *J Steroid Biochem*
411 *Mol Biol.* 2015;151:12-24. doi:10.1016/j.jsbmb.2014.10.020.
- 412 2. Evans RM. The steroid and thyroid hormone receptor superfamily. *Science.*
413 1988;240(4854):889-895. doi:10.1126/science.3283939.
- 414 3. Bridgham JT, Eick GN, Larroux C, et al. Protein evolution by molecular tinkering:
415 diversification of the nuclear receptor superfamily from a ligand-dependent ancestor. *PLoS*
416 *Biol.* 2010;8(10):e1000497. Published 2010 Oct 5. doi:10.1371/journal.pbio.1000497.
- 417 4. Baker ME, Funder JW, Kattoula SR. Evolution of hormone selectivity in glucocorticoid and
418 mineralocorticoid receptors [published correction appears in *J Steroid Biochem Mol Biol.*
419 2014 Jan;139:104]. *J Steroid Biochem Mol Biol.* 2013;137:57-70.
420 doi:10.1016/j.jsbmb.2013.07.009.
- 421 5. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. *Cell.*
422 2001;104(4):545-556. doi:10.1016/s0092-8674(01)00241-0.

- 423 6. Shibata S. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid
424 receptor and NaCl transport mechanisms in the renal distal nephron. *J Endocrinol.*
425 2017;234(1):T35-T47. doi:10.1530/JOE-16-0669.
- 426 7. Jaisser F, Farman N. Emerging Roles of the Mineralocorticoid Receptor in Pathology:
427 Toward New Paradigms in Clinical Pharmacology. *Pharmacol Rev.* 2016;68(1):49-75.
428 doi:10.1124/pr.115.011106.
- 429 8. Hanukoglu I, Hanukoglu A. Epithelial sodium channel (ENaC) family: Phylogeny,
430 structure-function, tissue distribution, and associated inherited diseases. *Gene.*
431 2016;579(2):95-132. doi:10.1016/j.gene.2015.12.061.
- 432 9. Joëls M, de Kloet ER. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The
433 brain mineralocorticoid receptor: a saga in three episodes. *J Endocrinol.* 2017
434 Jul;234(1):T49-T66. doi: 10.1530/JOE-16-0660. PMID: 28634266.
- 435 10. Gross KL, Cidlowski JA. Tissue-specific glucocorticoid action: a family affair. *Trends*
436 *Endocrinol Metab.* 2008;19(9):331-339. doi:10.1016/j.tem.2008.07.009.
- 437 11. Weikum ER, Knuesel MT, Ortlund EA, Yamamoto KR. Glucocorticoid receptor control of
438 transcription: precision and plasticity via allostery. *Nat Rev Mol Cell Biol.* 2017;18(3):159-
439 174. doi:10.1038/nrm.2016.152.
- 440 12. Thornton JW. Evolution of vertebrate steroid receptors from an ancestral estrogen receptor
441 by ligand exploitation and serial genome expansions. *Proc Natl Acad Sci U S A.* 2001 May
442 8;98(10):5671-6. doi: 10.1073/pnas.091553298. Epub 2001 May 1. PMID: 11331759;
443 PMCID: PMC33271.
- 444 13. Baker ME, Katsu Y. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR:
445 Evolution of the mineralocorticoid receptor: sequence, structure and function. *J Endocrinol.*
446 2017;234(1):T1-T16. doi:10.1530/JOE-16-0661.
- 447 14. Osório J, Rétaux S. The lamprey in evolutionary studies. *Dev Genes Evol.* 2008
448 May;218(5):221-35. doi: 10.1007/s00427-008-0208-1. Epub 2008 Feb 15. PMID:
449 18274775.
- 450 15. Bridgham JT, Carroll SM, Thornton JW. Evolution of hormone-receptor complexity by
451 molecular exploitation. *Science.* 2006;312(5770):97-101. doi:10.1126/science.1123348.
- 452 16. Carroll SM, Bridgham JT, Thornton JW. Evolution of hormone signaling in elasmobranchs
453 by exploitation of promiscuous receptors. *Mol Biol Evol.* 2008;25(12):2643-2652.
454 doi:10.1093/molbev/msn204.
- 455 17. Katsu Y, Shariful IMD, Lin X, Takagi W, Urushitani H, Kohno S, Hyodo S, Baker ME. N-
456 terminal Domain Regulates Steroid Activation of Elephant Shark Glucocorticoid and
457 Mineralocorticoid Receptors. *J Steroid Biochem Mol Biol.* 2021 Feb 27:105845. doi:
458 10.1016/j.jsbmb.2021.105845. Epub ahead of print. PMID: 33652098.

- 459 18. Inoue JG, Miya M, Lam K, et al. Evolutionary origin and phylogeny of the modern
460 holocephalans (Chondrichthyes: Chimaeriformes): a mitogenomic perspective. *Mol Biol*
461 *Evol.* 2010;27(11):2576-2586. doi:10.1093/molbev/msq147.
- 462 19. Venkatesh B, Lee AP, Ravi V, et al. Elephant shark genome provides unique insights into
463 gnathostome evolution [published correction appears in *Nature*. 2014 Sep
464 25;513(7519):574]. *Nature*. 2014;505(7482):174-179. doi:10.1038/nature12826.
- 465 20. Funder JW. Aldosterone and Mineralocorticoid Receptors-Physiology and
466 Pathophysiology. *Int J Mol Sci.* 2017 May 11;18(5):1032. doi: 10.3390/ijms18051032.
467 PMID: 28492512; PMCID: PMC5454944.
- 468 21. Hawkins UA, Gomez-Sanchez EP, Gomez-Sanchez CM, Gomez-Sanchez CE. The
469 ubiquitous mineralocorticoid receptor: clinical implications. *Curr Hypertens Rep.*
470 2012;14(6):573-580. doi:10.1007/s11906-012-0297-0.
- 471 22. Rossier BC, Baker ME, Studer RA. Epithelial sodium transport and its control by
472 aldosterone: the story of our internal environment revisited. *Physiol Rev.* 2015;95(1):297-
473 340. doi:10.1152/physrev.00011.2014.
- 474 23. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor
475 complementary DNA: structural and functional kinship with the glucocorticoid receptor.
476 *Science.* 1987;237(4812):268-275. doi:10.1126/science.3037703.
- 477 24. Katsu Y, Kohno S, Oka K, et al. Transcriptional activation of elephant shark
478 mineralocorticoid receptor by corticosteroids, progesterone, and spironolactone. *Sci Signal.*
479 2019;12(584):eaar2668. Published 2019 Jun 4. doi:10.1126/scisignal.aar2668, (n.d.).
- 480 25. Jiang JQ, Young G, Kobayashi T, Nagahama Y. Eel (*Anguilla japonica*) testis 11beta-
481 hydroxylase gene is expressed in interrenal tissue and its product lacks aldosterone
482 synthesizing activity. *Mol Cell Endocrinol.* 1998;146(1-2):207-211. doi:10.1016/s0303-
483 7207(98)00147-6.
- 484 26. Joss JM, Itahara Y, Watanabe TX, Nakajima K, Takei Y. Teleost-type angiotensin is
485 present in Australian lungfish, *Neoceratodus forsteri*. *Gen Comp Endocrinol.*
486 1999;114(2):206-212. doi:10.1006/gcen.1999.7246.
- 487 27. Joss JM. Lungfish evolution and development. *Gen Comp Endocrinol.* 2006 Sep
488 15;148(3):285-9. doi: 10.1016/j.ygcen.2005.10.010. Epub 2005 Dec 7. PMID: 16337631.
- 489 28. Uchiyama M, Maejima S, Yoshie S, Kubo Y, Konno N, Joss JM. The epithelial sodium
490 channel in the Australian lungfish, *Neoceratodus forsteri* (Osteichthyes: Dipnoi). *Proc Biol*
491 *Sci.* 2012;279(1748):4795-4802. doi:10.1098/rspb.2012.1945.
- 492 29. Meyer A, Schloissnig S, Franchini P, Du K, Woltering JM, Irisarri I, Wong WY,
493 Nowoshilow S, Kneitz S, Kawaguchi A, Fabrizius A, Xiong P, Dechaud C, Spaink HP,
494 Volff JN, Simakov O, Burmester T, Tanaka EM, Schartl M. Giant lungfish genome
495 elucidates the conquest of land by vertebrates. *Nature.* 2021 Feb;590(7845):284-289. doi:

- 496 10.1038/s41586-021-03198-8. Epub 2021 Jan 18. PMID: 33461212; PMCID:
497 PMC7875771.
- 498 30. Biscotti MA, Gerdol M, Canapa A, Forconi M, Olmo E, Pallavicini A, Barucca M, Scharl
499 M. The Lungfish Transcriptome: A Glimpse into Molecular Evolution Events at the
500 Transition from Water to Land. *Sci Rep.* 2016 Feb 24;6:21571. doi: 10.1038/srep21571.
501 PMID: 26908371; PMCID: PMC4764851.
- 502 31. Brinkmann H, Venkatesh B, Brenner S, Meyer A. Nuclear protein-coding genes support
503 lungfish and not the coelacanth as the closest living relatives of land vertebrates. *Proc Natl*
504 *Acad Sci U S A.* 2004 Apr 6;101(14):4900-5. doi: 10.1073/pnas.0400609101. Epub 2004
505 Mar 22. PMID: 15037746; PMCID: PMC387346.
- 506 32. Wang K, Wang J, Zhu C, Yang L, Ren Y, Ruan J, Fan G, Hu J, Xu W, Bi X, Zhu Y, Song
507 Y, Chen H, Ma T, Zhao R, Jiang H, Zhang B, Feng C, Yuan Y, Gan X, Li Y, Zeng H, Liu
508 Q, Zhang Y, Shao F, Hao S, Zhang H, Xu X, Liu X, Wang D, Zhu M, Zhang G, Zhao W,
509 Qiu Q, He S, Wang W. African lungfish genome sheds light on the vertebrate water-to-land
510 transition. *Cell.* 2021 Feb 4:S0092-8674(21)00090-8. doi: 10.1016/j.cell.2021.01.047. Epub
511 ahead of print. PMID: 33545087.
- 512 33. McCormick SD, Bradshaw D. Hormonal control of salt and water balance in vertebrates.
513 *Gen Comp Endocrinol.* 2006 May 15;147(1):3-8. doi: 10.1016/j.ygcen.2005.12.009. Epub
514 2006 Feb 2. PMID: 16457828.
- 515 34. Rossier BC. Osmoregulation during Long-Term Fasting in Lungfish and Elephant Seal: Old
516 and New Lessons for the Nephrologist. *Nephron.* 2016;134(1):5-9. doi:
517 10.1159/000444307. Epub 2016 Feb 23. PMID: 26901864.
- 518 35. Sugimoto A, Oka K, Sato R, Adachi S, Baker ME, Katsu Y. Corticosteroid and
519 progesterone transactivation of mineralocorticoid receptors from Amur sturgeon and
520 tropical gar. *Biochem J.* 2016;473(20):3655-3665. doi:10.1042/BCJ20160579.
- 521 36. Katsu Y, Baker ME. Progesterone activation of zebrafish mineralocorticoid receptor may
522 influence growth of some transplanted tumors. *Proc Natl Acad Sci U S A.*
523 2018;115(13):E2908-E2909. doi:10.1073/pnas.1802441115.
- 524 37. Fuller PJ, Yao YZ, Jin R, et al. Molecular evolution of the switch for progesterone and
525 spironolactone from mineralocorticoid receptor agonist to antagonist. *Proc Natl Acad Sci U*
526 *S A.* 2019;116(37):18578-18583. doi:10.1073/pnas.1903172116, (n.d.).
- 527 38. Sturm A, Bury N, Dengreville L, et al. 11-deoxycorticosterone is a potent agonist of the
528 rainbow trout (*Oncorhynchus mykiss*) mineralocorticoid receptor. *Endocrinology.*
529 2005;146(1):47-55. doi:10.1210/en.2004-0128.
- 530 39. Baker ME, Katsu Y. Progesterone: An enigmatic ligand for the mineralocorticoid receptor.
531 *Biochem Pharmacol.* 2020;177:113976. doi:10.1016/j.bcp.2020.113976.

- 532 40. Katsu Y, Oka K, Baker ME. Evolution of human, chicken, alligator, frog, and zebrafish
533 mineralocorticoid receptors: Allosteric influence on steroid specificity. *Sci Signal*.
534 2018;11(537):eaao1520. Published 2018 Jul 3. doi:10.1126/scisignal.aao1.
- 535 41. Baker ME, Funder JW, Kattoula SR. Evolution of hormone selectivity in glucocorticoid and
536 mineralocorticoid receptors [published correction appears in *J Steroid Biochem Mol Biol*.
537 2014 Jan;139:104]. *J Steroid Biochem Mol Biol*. 2013;137:57-70.
538 doi:10.1016/j.jsbmb.2013.07.009.
- 539 42. Close DA, Yun SS, McCormick SD, Wildbill AJ, Li W. 11-deoxycortisol is a corticosteroid
540 hormone in the lamprey. *Proc Natl Acad Sci U S A*. 2010 Aug 3;107(31):13942-7. doi:
541 10.1073/pnas.0914026107. Epub 2010 Jul 19. PMID: 20643930; PMCID: PMC2922276.
- 542 43. Shaughnessy CA, Barany A, McCormick SD. 11-Deoxycortisol controls hydromineral
543 balance in the most basal osmoregulating vertebrate, sea lamprey (*Petromyzon marinus*).
544 *Sci Rep*. 2020;10(1):12148. Published 2020 Jul 22. doi:10.1038/s41598-020-69061-4.
- 545 44. Bridgham JT, Carroll SM, Thornton JW. Evolution of hormone-receptor complexity by
546 molecular exploitation. *Science*. 2006;312(5770):97-101. doi:10.1126/science.1123348.
- 547 45. Conneely OM, Mulac-Jericevic B, DeMayo F, Lydon JP, O'Malley BW. Reproductive
548 functions of progesterone receptors. *Recent Prog Horm Res*. 2002;57:339-355.
549 doi:10.1210/rp.57.1.339.
- 550 46. Publicover S, Barratt C. Reproductive biology: Progesterone's gateway into sperm
551 [published correction appears in *Nature*. 2011 Mar 31;471(7340):589]. *Nature*.
552 2011;471(7338):313-314. doi:10.1038/471313a.
- 553 47. Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and
554 potassium-sparing diuretics. *J Clin Hypertens (Greenwich)*. 2011 Sep;13(9):644-8. doi:
555 10.1111/j.1751-7176.2011.00511.x. Epub 2011 Aug 9. PMID: 21896143.
- 556 48. Kolkhof P, Bäracker L. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR:
557 Mineralocorticoid receptor antagonists: 60 years of research and development. *J*
558 *Endocrinol*. 2017 Jul;234(1):T125-T140. doi: 10.1530/JOE-16-0600. PMID: 28634268;
559 PMCID: PMC5488394.
- 560 49. Fuse H, Kitagawa H, Kato S. Characterization of transactivational property and coactivator
561 mediation of rat mineralocorticoid receptor activation function-1 (AF-1). *Mol Endocrinol*.
562 2000 Jun;14(6):889-99. doi: 10.1210/mend.14.6.0467. PMID: 10847590.
- 563 50. Fischer K, Kelly SM, Watt K, Price NC, McEwan IJ. Conformation of the
564 Mineralocorticoid Receptor N-Terminal Domain: Evidence for Induced and Stable
565 Structure. *Mol Endocrinol*. 2010 Oct;24(10):1935-48. Doi: 10.1210/Me.2010-0005. Epub
566 2010 Aug 4. PMID: 20685853; PMCID: PMC5417395.”.

51. Pascual-Le Tallec L, Lombès M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. *Mol Endocrinol*. 2005 Sep;19(9):2211-21. doi: 10.1210/me.2005-0089. Epub 2005 Mar 31. PMID: 15802372.
52. Rupprecht R, Arriza JL, Spengler D, et al. Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. *Mol Endocrinol*. 1993;7(4):597-603. doi:10.1210/mend.7.4.8388999.
53. Iñiguez-Lluhí JA, Pearce D. A common motif within the negative regulatory regions of multiple factors inhibits their transcriptional synergy. *Mol Cell Biol*. 2000 Aug;20(16):6040-50. doi: 10.1128/mcb.20.16.6040-6050.2000. PMID: 10913186; PMCID: PMC86080.
54. Beato M, Arnemann J, Chalepakis G, Slater E, Willmann T. Gene regulation by steroid hormones. *J Steroid Biochem*. 1987;27(1-3):9-14. doi: 10.1016/0022-4731(87)90288-3. PMID: 2826895.
55. Cato AC, Skroch P, Weinmann J, Butkeraitis P, Ponta H. DNA sequences outside the receptor-binding sites differently modulate the responsiveness of the mouse mammary tumour virus promoter to various steroid hormones. *EMBO J*. 1988 May;7(5):1403-10. PMID: 2842149; PMCID: PMC458390.
56. Fuller PJ, Yao Y, Yang J, Young MJ. Mechanisms of ligand specificity of the mineralocorticoid receptor. *J Endocrinol*. 2012 Apr;213(1):15-24. doi: 10.1530/JOE-11-0372. Epub 2011 Dec 12. PMID: 22159507.
57. Lombes M, Kenouch S, Souque A, Farman N, Rafestin-Oblin ME. The Mineralocorticoid Receptor Discriminates Aldosterone from Glucocorticoids Independently of the 11 Beta-Hydroxysteroid Dehydrogenase. *Endocrinology*. 1994;135(3):834-840. Doi:10.1210/Endo.135.3.8070376.
58. Hellal-Levy C, Couette B, Fagart J, Souque A, Gomez-Sanchez C, Rafestin-Oblin M. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. *FEBS Lett*. 1999;464(1-2):9-13. doi:10.1016/s0014-5793(99)01667-1.
59. Mani O, Nashev LG, Livelo C, Baker ME, Odermatt A. Role of Pro-637 and Gln-642 in human glucocorticoid receptors and Ser-843 and Leu-848 in mineralocorticoid receptors in their differential responses to cortisol and aldosterone. *J Steroid Biochem Mol Biol*. 2016 May;159:31-40. doi: 10.1016/j.jsbmb.2016.02.017. Epub 2016 Feb 22. PMID: 26907965.
60. Pippal JB, Cheung CM, Yao YZ, Brennan FE, Fuller PJ. Characterization of the zebrafish (*Danio rerio*) mineralocorticoid receptor. *Mol Cell Endocrinol*. 2011 Jan 30;332(1-2):58-66. doi: 10.1016/j.mce.2010.09.014. Epub 2010 Oct 12. PMID: 20932876.
61. Kiilerich P, Triqueneaux G, Christensen NM, et al. Interaction between the trout mineralocorticoid and glucocorticoid receptors in vitro. *J Mol Endocrinol*. 2015;55(1):55-68. doi:10.1530/JME-15-0002.

- 605 62. Dobzhansky.T (1973) Nothing in Biology Makes Sense except in the Light of Evolution.
606 Am Biol Teach 35(3):125-129.
- 607 63. Fournier D, Luft FC, Bader M, Ganten D, Andrade-Navarro MA. Emergence and evolution
608 of the renin-angiotensin-aldosterone system. J Mol Med (Berl). 2012 May;90(5):495-508.
609 doi: 10.1007/s00109-012-0894-z. Epub 2012 Apr 14. PMID: 22527880; PMCID:
610 PMC3354321.
- 611 64. Vize PD, Smith HW. A Homeric view of kidney evolution: A reprint of H.W. Smith's
612 classic essay with a new introduction. Evolution of the kidney. 1943. Anat Rec A Discov
613 Mol Cell Evol Biol. 2004;277(2):344-354. doi:10.1002/ar.a.20017.
- 614 65. Xanthakis V, Vasan RS. Aldosterone and the risk of hypertension. Curr Hypertens Rep.
615 2013 Apr;15(2):102-7. doi: 10.1007/s11906-013-0330-y. PMID: 23378101; PMCID:
616 PMC3619380.
- 617 66. Funder JW. Apparent mineralocorticoid excess. J Steroid Biochem Mol Biol. 2017
618 Jan;165(Pt A):151-153. doi: 10.1016/j.jsbmb.2016.03.010. Epub 2016 Mar 5. PMID:
619 26956190.
- 620 67. Frey FJ, Odermatt A, Frey BM. Glucocorticoid-mediated mineralocorticoid receptor
621 activation and hypertension. Curr Opin Nephrol Hypertens. 2004 Jul;13(4):451-8. doi:
622 10.1097/01.mnh.0000133976.32559.b0. PMID: 15199296.
- 623 68. Chapman K, Holmes M, Seckl J. 11 β -hydroxysteroid dehydrogenases: intracellular gate-
624 keepers of tissue glucocorticoid action. Physiol Rev. 2013;93(3):1139-1206.
625 doi:10.1152/physrev.00020.2012.
- 626 69. Funder J. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid
627 receptor activation and specificity-conferring mechanisms: a brief history. J Endocrinol.
628 2017 Jul;234(1):T17-T21. doi: 10.1530/JOE-17-0119. Epub 2017 May 22. PMID:
629 28533421.
- 630 70. Fuller PJ, Yao YZ, Yang J, Young MJ. Structural determinants of activation of the
631 mineralocorticoid receptor: an evolutionary perspective. J Hum Hypertens. 2021
632 Feb;35(2):110-116. doi: 10.1038/s41371-020-0360-2. Epub 2020 May 28. PMID:
633 32467588.
- 634 71. Hilser VJ, Thompson EB. Structural dynamics, intrinsic disorder, and allostery in nuclear
635 receptors as transcription factors. J Biol Chem. 2011;286(46):39675-39682.
636 doi:10.1074/jbc.R111.278929.
- 637 72. Changeux JP, Christopoulos A. Allosteric Modulation as a Unifying Mechanism for
638 Receptor Function and Regulation. Cell. 2016 Aug 25;166(5):1084-1102. doi:
639 10.1016/j.cell.2016.08.015. PMID: 27565340.
- 640 73. Oka K, Hoang A, Okada D, Iguchi T, Baker ME, Katsu Y. Allosteric role of the amino-
641 terminal A/B domain on corticosteroid transactivation of gar and human glucocorticoid

642 receptors. J Steroid Biochem Mol Biol. 2015;154:112-119.
643 doi:10.1016/j.jsbmb.2015.07.025.

644